4.5 Review

Cysteine cathepsins as therapeutic targets in inflammatory diseases

Journal

EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 24, Issue 6, Pages 573-588

Publisher

TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2020.1746765

Keywords

Biomarkers; cysteine cathepsins; diagnostics; inflammation-associated diseases; inhibition; theranostics

Funding

  1. Slovene Research Agency [P1-0140, N1-0127, J1-1710]
  2. ICGEB [CRP/SVN 16-01]

Ask authors/readers for more resources

Introduction: Cysteine cathepsins are involved in the development and progression of numerous inflammation-associated diseases such as cancer, arthritis, bone and immune disorders. Consequently, there is a drive to progress research efforts focused on cathepsin use in diagnostics and as therapeutic targets in disease. Areas covered: This review discusses the potential of cysteine cathepsins as therapeutic targets in inflammation-associated diseases and recent advances in preclinical and clinical research. We describe direct targeting of cathepsins for treatment purposes and their indirect use in diagnostics. Expert opinion: The targeting of cysteine cathepsins has not translated into the clinic; this failure is attributed to off- and on-target side effects and/or the lack of companion biomarkers. This field now embraces developments in diagnostic imaging, the activation of prodrugs and antibody-drug conjugates for targeted drug delivery. The future lies in improved molecular tools and therapeutic concepts that will find a wide spectrum of uses in diagnostic and therapeutic applications.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available